Dapagliflozin Confers More Favorable Cardiometabolic Outcomes Vs Vildagliptin | Latest News RSS feed

Dapagliflozin Confers More Favorable Cardiometabolic Outcomes Vs Vildagliptin - Latest News


Dapagliflozin confers more favorable cardiometabolic outcomes vs. vildagliptin

CHICAGO — The SGLT2 inhibitor dapagliflozin was more beneficial than the DDP4 inhibitor vildagliptin in reducing BMI and systolic BP and improving other cardiometabolic outcomes among patients with ty... read more

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health. read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us